Literature DB >> 34046629

Pyridazinone derivatives as potential anti-inflammatory agents: synthesis and biological evaluation as PDE4 inhibitors.

Ingrid Allart-Simon1, Aurélie Moniot2, Nicolo Bisi1, Miguel Ponce-Vargas1, Sandra Audonnet3, Marie Laronze-Cochard1, Janos Sapi1, Eric Hénon1, Frédéric Velard2, Stéphane Gérard1.   

Abstract

Cyclic nucleotide phosphodiesterase type 4 (PDE4), which controls the intracellular level of cyclic adenosine monophosphate (cAMP), has aroused scientific attention as a suitable target for anti-inflammatory therapy of respiratory diseases. This work describes the development and characterization of pyridazinone derivatives bearing an indole moiety as potential PDE4 inhibitors and their evaluation as anti-inflammatory agents. Among these derivatives, 4-(5-methoxy-1H-indol-3-yl)-6-methylpyridazin-3(2H)-one possesses promising activity, and selectivity towards PDE4B isoenzymes and is able to regulate potent pro-inflammatory cytokine and chemokine production by human primary macrophages. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34046629      PMCID: PMC8127987          DOI: 10.1039/d0md00423e

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  42 in total

Review 1.  PDE4 inhibitors - a review of the current field.

Authors:  Neil J Press; Katharine H Banner
Journal:  Prog Med Chem       Date:  2009

2.  Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents.

Authors:  Chantal Barberot; Aurélie Moniot; Ingrid Allart-Simon; Laurette Malleret; Tatiana Yegorova; Marie Laronze-Cochard; Abderrazzaq Bentaher; Maurice Médebielle; Jean-Philippe Bouillon; Eric Hénon; Janos Sapi; Frédéric Velard; Stéphane Gérard
Journal:  Eur J Med Chem       Date:  2018-01-17       Impact factor: 6.514

3.  Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages.

Authors:  S-L Catherine Jin; Linda Lan; Maria Zoudilova; Marco Conti
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

4.  Correlating macrophage morphology and cytokine production resulting from biomaterial contact.

Authors:  Hyun-Su Lee; Stanley J Stachelek; Nancy Tomczyk; Matthew J Finley; Russell J Composto; David M Eckmann
Journal:  J Biomed Mater Res A       Date:  2012-07-30       Impact factor: 4.396

5.  Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD.

Authors:  S L Traves; S V Culpitt; R E K Russell; P J Barnes; L E Donnelly
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

Review 6.  Disease phenotyping in chronic obstructive pulmonary disease: the neutrophilic endotype.

Authors:  Derek W Russell; J Michael Wells; J Edwin Blalock
Journal:  Curr Opin Pulm Med       Date:  2016-03       Impact factor: 3.155

7.  Human lung and monocyte-derived macrophages differ with regard to the effects of β2-adrenoceptor agonists on cytokine release.

Authors:  Tatiana Victoni; Hélène Salvator; Charlotte Abrial; Marion Brollo; Luis Cristovão Sobrino Porto; Vincent Lagente; Emmanuel Naline; Stanislas Grassin-Delyle; Philippe Devillier
Journal:  Respir Res       Date:  2017-06-21

8.  Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis.

Authors:  Yanan Cui; Lijuan Luo; Chenbei Li; Ping Chen; Yan Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-11-22

9.  Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study).

Authors:  Nicolas Roche; Vicente Plaza; Vibeke Backer; Job van der Palen; Isa Cerveri; Chelo Gonzalez; Guilherme Safioti; Irma Scheepstra; Oliver Patino; Dave Singh
Journal:  NPJ Prim Care Respir Med       Date:  2020-01-07       Impact factor: 2.871

Review 10.  Inflammatory mechanisms in patients with chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  J Allergy Clin Immunol       Date:  2016-05-27       Impact factor: 10.793

View more
  4 in total

1.  Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity.

Authors:  Niccolo Cantini; Igor A Schepetkin; Nadezhda V Danilenko; Andrei I Khlebnikov; Letizia Crocetti; Maria Paola Giovannoni; Liliya N Kirpotina; Mark T Quinn
Journal:  Molecules       Date:  2022-06-10       Impact factor: 4.927

2.  Inhibition of Recruitment and Activation of Neutrophils by Pyridazinone-Scaffold-Based Compounds.

Authors:  Aurélie Moniot; Julien Braux; Renaud Siboni; Christine Guillaume; Sandra Audonnet; Ingrid Allart-Simon; Janos Sapi; Rabindra Tirouvanziam; Stéphane Gérard; Sophie C Gangloff; Frédéric Velard
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

3.  Pyridazinone Derivatives Limit Osteosarcoma-Cells Growth In Vitro and In Vivo.

Authors:  Aurélie Moniot; Julien Braux; Camille Bour; Christine Guillaume; Fabien Lamret; Ingrid Allart-Simon; Sandra Audonnet; Sarah Renault; Francoise Rédini; Marie Laronze-Cochard; Janos Sapi; Sophie C Gangloff; Stéphane Gérard; Frédéric Velard
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

4.  Autoxidation of 4-Hydrazinylquinolin-2(1H)-one; Synthesis of Pyridazino[4,3-c:5,6-c']diquinoline-6,7(5H,8H)-diones.

Authors:  Sara M Mostafa; Ashraf A Aly; Alaa A Hassan; Esraa M Osman; Stefan Bräse; Martin Nieger; Mahmoud A A Ibrahim; Asmaa H Mohamed
Journal:  Molecules       Date:  2022-03-25       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.